Sign in

    Mike Murray

    Senior Associate in Equity Research at RBC Capital Markets

    Mike Murray is a Senior Associate in Equity Research at RBC Capital Markets, specializing in coverage of major technology companies, including Apple. With expertise in analyzing sector trends, Murray supports the technology research team by producing detailed company reports and investment recommendations. He joined RBC following earlier roles in finance and has steadily advanced to his current research position. Murray holds relevant FINRA securities licenses and is recognized for his analytical rigor and teamwork within one of Wall Street’s prominent technology equity research groups.

    Mike Murray's questions to TENET HEALTHCARE (THC) leadership

    Mike Murray's questions to TENET HEALTHCARE (THC) leadership • Q4 2024

    Question

    Mike Murray, on for Ben Hendrix, asked for growth expectations for ASC total joint procedures and for an update on progress and acceleration of cardiology procedures in ASCs.

    Answer

    Dr. Saum Sutaria, Chairman and CEO, confirmed continued focus on orthopedics but declined to provide service-line specific guidance. Regarding cardiology, he sees a long-term opportunity but expects a slower evolution than many anticipate due to patient safety, payer mix, and high capital requirements. He stated Tenet will participate but will not rush development.

    Ask Fintool Equity Research AI

    Mike Murray's questions to Addus HomeCare (ADUS) leadership

    Mike Murray's questions to Addus HomeCare (ADUS) leadership • Q3 2024

    Question

    Mike Murray, on behalf of Ben Hendrix at RBC Capital Markets, asked about the competitive dynamics in hospice given softer admissions and whether same-store ADC growth would continue to improve. He also asked what home health same-store growth would have been excluding the markets undergoing operational investments.

    Answer

    President and COO Brad Bickham expressed optimism that hospice same-store growth will continue to improve sequentially, targeting mid-to-upper single-digit growth with the help of new sales leadership. For home health, he noted that a market that previously completed the operational changes saw growth in the 2-3% range, indicating potential for improvement once the current initiatives are finished.

    Ask Fintool Equity Research AI